Physician profile
David D Brown
NPI 1669652533
$10,375.98
in general payments reported to CMS, 2019-2025
41 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.60 · 2020: $1,102 · 2021: $1,273 · 2022: $1,799 · 2023: $2,200 · 2024: $2,160 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,665 · Education: $305 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,664.50 |
| Education | $304.98 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,386.72 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $1,080.39 | 2020-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $960.04 | 2019-2025 | |
| Ucb, INC. | $957.69 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Biogen, INC. | $885.68 | 2020-2024 | Tysabri, Tysabri, Vumerity |
| Lilly USA, LLC | $685.82 | 2020-2025 | Emgality, Reyvow, Kisunla |
| Sk Life Science, INC. | $616.66 | 2020-2025 | Xcopri |
| Pfizer INC. | $344.11 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $324.42 | 2020-2025 | Crexont, Rytary |
| Neurocrine Biosciences, INC. | $323.98 | 2020-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $317.87 | 2022-2024 | Ultomiris, Soliris |
| Scilex Pharmaceuticals INC. | $287.79 | 2023-2024 | Ztlido |
| Amgen INC. | $219.35 | 2021-2025 | Uplizna, Aimovig |
| Averitas Pharma INC. | $183.29 | 2024 | Qutenza |
| Eisai INC. | $151.59 | 2021-2024 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.